COVID-19: The Immune Responses and Clinical Therapy Candidates.
Zhand, S
Saghaeian Jazi, M
Mohammadi, S
Tarighati Rasekhi, R
Rostamian, G
Kalani, MR
Rostamian, A
George, J
Douglas, MW
- Publisher:
- MDPI AG
- Publication Type:
- Journal Article
- Citation:
- International Journal of Molecular Sciences, 2020, 21, (15)
- Issue Date:
- 2020-08-03
Open Access
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is open access.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Zhand, S | |
dc.contributor.author | Saghaeian Jazi, M | |
dc.contributor.author | Mohammadi, S | |
dc.contributor.author | Tarighati Rasekhi, R | |
dc.contributor.author | Rostamian, G | |
dc.contributor.author | Kalani, MR | |
dc.contributor.author | Rostamian, A | |
dc.contributor.author | George, J | |
dc.contributor.author | Douglas, MW | |
dc.date.accessioned | 2021-05-26T01:17:15Z | |
dc.date.available | 2020-07-31 | |
dc.date.available | 2021-05-26T01:17:15Z | |
dc.date.issued | 2020-08-03 | |
dc.identifier.citation | International Journal of Molecular Sciences, 2020, 21, (15) | |
dc.identifier.issn | 1422-0067 | |
dc.identifier.issn | 1422-0067 | |
dc.identifier.uri | http://hdl.handle.net/10453/149224 | |
dc.description.abstract | The pandemic of coronavirus disease 2019 (COVID-19), with rising numbers of patients worldwide, presents an urgent need for effective treatments. To date, there are no therapies or vaccines that are proven to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several potential candidates or repurposed drugs are under investigation, including drugs that inhibit SARS-CoV-2 replication and block infection. The most promising therapy to date is remdesivir, which is US Food and Drug Administration (FDA) approved for emergency use in adults and children hospitalized with severe suspected or laboratory-confirmed COVID-19. Herein we summarize the general features of SARS-CoV-2's molecular and immune pathogenesis and discuss available pharmacological strategies, based on our present understanding of SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) infections. Finally, we outline clinical trials currently in progress to investigate the efficacy of potential therapies for COVID-19. | |
dc.format | Electronic | |
dc.language | eng | |
dc.publisher | MDPI AG | |
dc.relation.ispartof | International Journal of Molecular Sciences | |
dc.relation.isbasedon | 10.3390/ijms21155559 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | 0399 Other Chemical Sciences, 0604 Genetics, 0699 Other Biological Sciences | |
dc.subject.classification | Chemical Physics | |
dc.subject.mesh | Adaptive Immunity | |
dc.subject.mesh | Anti-Inflammatory Agents | |
dc.subject.mesh | Antiviral Agents | |
dc.subject.mesh | Betacoronavirus | |
dc.subject.mesh | Coronavirus Infections | |
dc.subject.mesh | COVID-19 | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Immunotherapy | |
dc.subject.mesh | Middle East Respiratory Syndrome Coronavirus | |
dc.subject.mesh | Open Reading Frames | |
dc.subject.mesh | Pandemics | |
dc.subject.mesh | Pneumonia, Viral | |
dc.subject.mesh | SARS-CoV-2 | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Pneumonia, Viral | |
dc.subject.mesh | Coronavirus Infections | |
dc.subject.mesh | Anti-Inflammatory Agents | |
dc.subject.mesh | Antiviral Agents | |
dc.subject.mesh | Immunotherapy | |
dc.subject.mesh | Open Reading Frames | |
dc.subject.mesh | Adaptive Immunity | |
dc.subject.mesh | Pandemics | |
dc.subject.mesh | Middle East Respiratory Syndrome Coronavirus | |
dc.subject.mesh | Betacoronavirus | |
dc.subject.mesh | COVID-19 | |
dc.subject.mesh | SARS-CoV-2 | |
dc.subject.mesh | Adaptive Immunity | |
dc.subject.mesh | Anti-Inflammatory Agents | |
dc.subject.mesh | Antiviral Agents | |
dc.subject.mesh | Betacoronavirus | |
dc.subject.mesh | COVID-19 | |
dc.subject.mesh | Coronavirus Infections | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Immunotherapy | |
dc.subject.mesh | Middle East Respiratory Syndrome Coronavirus | |
dc.subject.mesh | Open Reading Frames | |
dc.subject.mesh | Pandemics | |
dc.subject.mesh | Pneumonia, Viral | |
dc.subject.mesh | SARS-CoV-2 | |
dc.title | COVID-19: The Immune Responses and Clinical Therapy Candidates. | |
dc.type | Journal Article | |
utslib.citation.volume | 21 | |
utslib.location.activity | Switzerland | |
utslib.for | 0399 Other Chemical Sciences | |
utslib.for | 0604 Genetics | |
utslib.for | 0699 Other Biological Sciences | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Engineering and Information Technology | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering | |
utslib.copyright.status | open_access | * |
pubs.consider-herdc | true | |
dc.date.updated | 2021-05-26T01:17:11Z | |
pubs.issue | 15 | |
pubs.publication-status | Published | |
pubs.volume | 21 | |
utslib.citation.issue | 15 |
Abstract:
The pandemic of coronavirus disease 2019 (COVID-19), with rising numbers of patients worldwide, presents an urgent need for effective treatments. To date, there are no therapies or vaccines that are proven to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several potential candidates or repurposed drugs are under investigation, including drugs that inhibit SARS-CoV-2 replication and block infection. The most promising therapy to date is remdesivir, which is US Food and Drug Administration (FDA) approved for emergency use in adults and children hospitalized with severe suspected or laboratory-confirmed COVID-19. Herein we summarize the general features of SARS-CoV-2's molecular and immune pathogenesis and discuss available pharmacological strategies, based on our present understanding of SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) infections. Finally, we outline clinical trials currently in progress to investigate the efficacy of potential therapies for COVID-19.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph